GRTS
Price:
$0.0322
Market Cap:
$3.80M
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine pl...[Read more]
Industry
Biotechnology
IPO Date
2018-09-28
Stock Exchange
NASDAQ
Ticker
GRTS
According to Gritstone bio, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 54.12M. This represents a change of -77.77% compared to the average of 243.50M of the last 4 quarters.
The mean historical Enterprise Value of Gritstone bio, Inc. over the last ten years is 302.46M. The current 54.12M Enterprise Value has changed 1.69% with respect to the historical average. Over the past ten years (40 quarters), GRTS's Enterprise Value was at its highest in in the December 2021 quarter at 933.32M. The Enterprise Value was at its lowest in in the September 2018 quarter at -22541392.85.
Average
302.46M
Median
270.38M
Minimum
3.94M
Maximum
947.60M
Discovering the peaks and valleys of Gritstone bio, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 23.92%
Maximum Annual Enterprise Value = 947.60M
Minimum Annual Increase = -98.52%
Minimum Annual Enterprise Value = 3.94M
Year | Enterprise Value | Change |
---|---|---|
2023 | 275.17M | -7.81% |
2022 | 298.49M | -68.50% |
2021 | 947.60M | 23.92% |
2020 | 3.94M | -98.52% |
2019 | 267.07M | 177.88% |
2018 | 96.11M | -62.69% |
2017 | 257.61M | -5.87% |
The current Enterprise Value of Gritstone bio, Inc. (GRTS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
507.08M
5-year avg
358.45M
10-year avg
302.46M
Gritstone bio, Inc.’s Enterprise Value is less than Aurinia Pharmaceuticals Inc. (1.08B), less than BridgeBio Pharma, Inc. (5.92B), less than Annovis Bio, Inc. (109.96M), less than ImmunoGen, Inc. (8.19B), less than Generation Bio Co. (209.62M), greater than Kronos Bio, Inc. (14.20M), less than Erasca, Inc. (691.95M), less than C4 Therapeutics, Inc. (462.75M), less than Edgewise Therapeutics, Inc. (3.19B), greater than Kezar Life Sciences, Inc. (41.06M), less than Fulcrum Therapeutics, Inc. (126.38M), greater than Passage Bio, Inc. (38.72M), less than InflaRx N.V. (66.26M), less than Allogene Therapeutics, Inc. (550.88M), less than G1 Therapeutics, Inc. (410.58M), less than Heron Therapeutics, Inc. (430.30M), less than Annexon, Inc. (621.99M), less than Sangamo Therapeutics, Inc. (363.62M), greater than Affimed N.V. (49.51M), less than Leap Therapeutics, Inc. (62.43M), greater than Adaptimmune Therapeutics plc (40.05M), less than Corvus Pharmaceuticals, Inc. (550.07M), greater than Aptose Biosciences Inc. (-306979.00),
Company | Enterprise Value | Market cap |
---|---|---|
1.08B | $1.03B | |
5.92B | $4.74B | |
109.96M | $113.96M | |
8.19B | $8.73B | |
209.62M | $144.16M | |
14.20M | $57.28M | |
691.95M | $810.79M | |
462.75M | $455.30M | |
3.19B | $3.23B | |
41.06M | $51.73M | |
126.38M | $203.43M | |
38.72M | $37.34M | |
66.26M | $91.86M | |
550.88M | $627.34M | |
410.58M | $377.75M | |
430.30M | $269.97M | |
621.99M | $749.09M | |
363.62M | $362.30M | |
49.51M | $49.79M | |
62.43M | $140.43M | |
40.05M | $204.51M | |
550.07M | $564.21M | |
-306979.00 | $7.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gritstone bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gritstone bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Gritstone bio, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Gritstone bio, Inc. (GRTS)?
What is the 3-year average Enterprise Value for Gritstone bio, Inc. (GRTS)?
What is the 5-year average Enterprise Value for Gritstone bio, Inc. (GRTS)?
How does the current Enterprise Value for Gritstone bio, Inc. (GRTS) compare to its historical average?